Semavik

    verified Drugs for the treatment of diabetes mellitus

    imagePackage photo coming soon

    info General information

    Name Semavik, 1.34 mg/mL (0.25/0.5/1 mg/dose), solution for subcutaneous administration
    INN Semaglutide
    Active substance Semaglutide
    Pharmacotherapeutic group Drugs used in diabetes. Blood glucose lowering drugs, excl. insulins. Glucagon-like peptide-1 (GLP-1) analogues. Semaglutide.
    Dosage form Solution for subcutaneous administration.
    Packaging

    3 mL of the product in colorless glass cartridges.

    The cartridge is installed in a plastic multi-dose disposable pen injector for repeated injections.

    1 pre-filled multi-dose disposable pen injector for repeated injections and 1 cardboard box containing 4 or 9 disposable needles are placed in a cardboard box.

    Manufacturer Karaganda Pharmaceutical Complex LLP EU GMP

    assignment_turned_in Indications

    Semavik is indicated for adult patients with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

    • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
    • in addition to other medicines for the treatment of diabetes.